miRagen Clinical Trials
miRagen has three product candidates in clinical development:
- Cobomarsen (MRG-106), an inhibitor of microRNA-155, is being developed for the treatment of blood cancers
- Remlarsen (MRG-201), a synthetic replacement of microRNA-29 is being developed for the treatment or prevention of pathologic fibrosis
- MRG-110 (S95010), an inhibitor of microRNA-92, is being developed in collaboration with Servier for the treatment of heart failure or other ischemic conditions where blood flow into tissues is compromised
If you are a patient, please click here.